OLD Mission Capital LLC Makes New $43.28 Million Investment in Novo Nordisk A/S (NYSE:NVO)

OLD Mission Capital LLC purchased a new position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 503,079 shares of the company's stock, valued at approximately $43,275,000. Novo Nordisk A/S accounts for 0.7% of OLD Mission Capital LLC's investment portfolio, making the stock its 12th biggest holding.

A number of other large investors also recently bought and sold shares of the stock. GQG Partners LLC grew its position in Novo Nordisk A/S by 74.7% in the 4th quarter. GQG Partners LLC now owns 12,994,533 shares of the company's stock valued at $1,117,790,000 after acquiring an additional 5,556,460 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of Novo Nordisk A/S during the fourth quarter worth about $404,910,000. Loomis Sayles & Co. L P raised its holdings in Novo Nordisk A/S by 34.2% in the fourth quarter. Loomis Sayles & Co. L P now owns 11,571,686 shares of the company's stock valued at $995,397,000 after acquiring an additional 2,947,771 shares in the last quarter. Clearbridge Investments LLC lifted its stake in Novo Nordisk A/S by 59.8% in the fourth quarter. Clearbridge Investments LLC now owns 4,283,317 shares of the company's stock worth $368,451,000 after acquiring an additional 1,602,549 shares during the last quarter. Finally, Sustainable Growth Advisers LP increased its position in shares of Novo Nordisk A/S by 23.6% in the 4th quarter. Sustainable Growth Advisers LP now owns 5,340,803 shares of the company's stock valued at $459,416,000 after purchasing an additional 1,021,498 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company's stock.

Novo Nordisk A/S Trading Down 5.9 %

Shares of NYSE:NVO traded down $3.95 during midday trading on Friday, reaching $63.15. The company's stock had a trading volume of 5,530,910 shares, compared to its average volume of 5,614,924. The business has a 50 day moving average price of $81.36 and a 200 day moving average price of $97.26. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. Novo Nordisk A/S has a 1 year low of $62.89 and a 1 year high of $148.15. The firm has a market cap of $283.41 billion, a price-to-earnings ratio of 19.15, a price-to-earnings-growth ratio of 0.90 and a beta of 0.61.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating analysts' consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Research analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be given a dividend of $0.7874 per share. This represents a yield of 1.2%. This is a boost from Novo Nordisk A/S's previous semi-annual dividend of $0.51. The ex-dividend date is Monday, March 31st. Novo Nordisk A/S's dividend payout ratio is 47.72%.

Wall Street Analyst Weigh In

Several research analysts have commented on the company. StockNews.com lowered Novo Nordisk A/S from a "strong-buy" rating to a "buy" rating in a research report on Friday, March 21st. BMO Capital Markets dropped their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an "outperform" rating on the stock in a research note on Monday, December 23rd. Stifel Nicolaus downgraded shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. Sanford C. Bernstein upgraded Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a research report on Monday, January 6th. Finally, UBS Group raised Novo Nordisk A/S from a "sell" rating to a "buy" rating in a report on Wednesday, January 8th. Three research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Novo Nordisk A/S presently has an average rating of "Moderate Buy" and a consensus price target of $145.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.